Table 3.
Univariate and multivariate analyses for OS.
| Characteristic | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Gender | ||||
| Male | Reference | Reference | ||
| Female | 0.74 (0.65-0.85) | <.001 | 0.78 (0.68-0.90) | .001 |
| Smoking history | ||||
| Current | Reference | |||
| Former | 0.90 (0.78-1.03) | .13 | ||
| Never | 0.79 (0.61-1.02) | .08 | ||
| Stage | ||||
| IIIB | Reference | Reference | ||
| IV M1a | 1.44 (0.85-2.44) | .18 | 1.70 (1.00-2.90) | .05 |
| IV M1b | 2.21 (1.32-3.70) | .003 | 2.34 (1.39-3.94) | .001 |
| Recurrent | 1.69 (0.92-3.09) | .09 | 1.62 (0.88-2.98) | .12 |
| Unknown | 7.48 (0.98-56.91) | .05 | 7.20 (0.91-57.31) | .06 |
| ECOG | ||||
| 0 | Reference | Reference | ||
| 1 | 1.45 (1.3-1.7) | <.001 | 1.38 (1.20-1.59) | <.001 |
| Histology | ||||
| Other | Reference | Reference | ||
| Adenocarcinoma | 0.738 (0.59-0.92) | .007 | 0.74 (0.59-0.93) | .009 |
| Hilar nodal metastases | ||||
| Absent | Reference | |||
| Present | 1.09 (0.97-1.2) | .17 | ||
| Mediastinal nodal metastases | ||||
| Absent | Reference | Reference | ||
| Present | 1.14 (1-1.3) | .04 | 1.15 (1.00-1.31) | .05 |
| Brain metastases | ||||
| Absent | Reference | |||
| Present | 1.04 (0.88-1.2) | .66 | ||
| Maintenance therapy arm | ||||
| Bevacizumab | Reference | Reference | ||
| Pemetrexed | 0.87 (0.71-1.07) | .17 | 0.85 (0.69-1.04) | .12 |
| Bevacizumab + pemetrexed | 0.89 (0.72-1.09) | .26 | 0.89 (0.73-1.10) | .30 |
| None | 2.36 (1.96-2.84) | <.001 | 2.30 (1.90-2.77) | <.001 |
| Response heterogeneity category | ||||
| HR | Reference | Reference | ||
| MR | 0.99 (0.83-1.18) | .91 | 0.91 (0.76-1.09) | .3 |
| TMR | 1.71 (1.41-2.06) | <.001 | 1.48 (1.22-1.79) | <.001 |